ADOPT Phase 4 Interim Analysis: Avatrombopag in Chronic ITP
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, posted on LinkedIn:
”ADOPT Phase 4 interim analysis: Avatrombopag in chronic ITP
Pleased to share this ASH poster as one of the co-authors. The interim dataset provides useful real-world evidence on avarombopag efficacy and safety in clinical practice.
Study overview:
– 199 patients | Mean 9.7 years from ITP diagnosis to enrollment
– 52.3 weeks median avarombopag dosing duration
– 44.1 cumulative weeks with platelet counts ≥30×10⁹/L
– 59.3% had received prior TPO-RA therapy—reflecting a population with established disease
Health-related quality of life outcomes:
→ EQ-5D-5L: improvements in mobility, usual activities, and pain/discomfort from enrollment to month 12
→ FACIT-Fatigue scores: consistent improvement across follow-up
→ WPAI: measurable reductions in work absenteeism, presenteeism, and overall impairment
→ ITP-PAQ: higher scores at month 12 across multiple scales
Safety findings:
18.1% adverse event rate | 12.6% serious AEs | 5.5% treatment-related AEs | 2.0% discontinued due to AEs
The data demonstrates sustained platelet control alongside functional improvements in work and daily activities. This aligns with our broader understanding of how effective haemostatic management translates to patient-reported outcomes.
The full analysis continues. Worth reviewing if you’re managing patients on TPO-RA therapy or evaluating treatment efficacy beyond platelet counts alone. ”
Stay updated with Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy